We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Fifth-Generation Cardiac Troponin Assays Compared

By LabMedica International staff writers
Posted on 20 Aug 2018
Cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are highly specific biomarkers of myocardial injury. More...
The 99th percentile upper reference limit (URL) of a normal reference population is the recommended threshold which defines an increased cTnI or cTnT plasma concentration indicative for myocardial injury.

In Europe, physicians have been using the so-called high-sensitivity cTnI (hs-cTnI) and high-sensitivity cTnT (hs-cTnT) assays for several years in clinical routine. These high-sensitivity assays, which are more analytically sensitive than former assays for the measurement of cardiac troponins, are also termed 5th generation assays.

Medical laboratory scientists at the Konventhospital Barmherzige Brueder Linz (Linz, Austria) studied 3,588 consecutive patients presenting to an emergency department. In a retrospective study they measured hs-cTnT plasma concentrations with the 5th generation “Troponin T hs” assay on a modular platform in clinical routine since January 2010.

Due to a changeover of their analytical systems, they switched to the 5th generation “STAT High Sensitive Troponin-I" assay by using an ARCH-ITECT i2000SR analyzer for clinical routine use in our hospitals since February 2013. The team assessed the capabilities of hs-cTnI and hs-cTnT for the prediction of 3.7 year all-cause mortality; discordant diagnoses of myocardial injury by hs-cTnI and hs-cTnT according to the European gender-neutral 99th percentile upper reference limits (i.e., 26 ng/L and 14 ng/L, respectively); and (3) analyte kinetics in patient with serial troponin measurements.

The scientists reported that with respect to prognosis of all-cause mortality, the AUC of hs-cTnI was 0.81 (95% CI, 0.80–0.82), and the AUC of hs-cTnT was 0.85 (95% CI, 0.84–0.86). With respect to discordant diagnoses, 21% of the 3,588 patients were classified as having myocardial injury by hs-cTnT but not by hs-cTnI, and less than 1% were classified as having myocardial injury by hs-cTnI but not by hs-cTnT. In the patients with serial blood sampling, the median delta values were 6.3 ng/L and 25% for hs-cTnI, and 4.2 ng/L and 16% for hs-cTnT.

The authors concluded that they had found different characteristics of the Abbott hs-cTnI and the Roche hs-cTnT assays, especially when using the European gender-neutral 99th percentile upper reference limits. Clinically, these different characteristics are related to discordant results in the diagnosis and prognosis of patients presenting to an emergency department. The study has been available online since June 27, 2018, in the journal Clinica Chimica Acta.

Related Links:
Konventhospital Barmherzige Brueder Linz


New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Semi-Automated Urine Chemistry Strip Reader
Mispa U500
New
Automated Phenotypic Screening Kit
MDRO Line Kits
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.